Rivastigmine: Uses, Dosage & Side Effects
A dual cholinesterase inhibitor used to treat mild to moderately severe Alzheimer's disease dementia and dementia associated with Parkinson's disease in adults
Rivastigmine is a dual cholinesterase inhibitor used to treat mild to moderately severe dementia caused by Alzheimer's disease and, in its oral capsule form, dementia associated with Parkinson's disease. In these conditions, certain nerve cells in the brain degenerate, reducing levels of the neurotransmitter acetylcholine. Rivastigmine blocks both acetylcholinesterase and butyrylcholinesterase – the two enzymes that break down acetylcholine – thereby increasing its levels in the brain and helping to reduce the cognitive and functional symptoms of dementia. Available as hard capsules in four strengths (1.5 mg, 3 mg, 4.5 mg, and 6 mg), rivastigmine is prescription only and is taken twice daily with food. It is marketed internationally under several brand names, including Rivastigmine 1 A Pharma and the originator brand Exelon.
Quick Facts: Rivastigmine
Key Takeaways
- Rivastigmine is a dual cholinesterase inhibitor that blocks both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), raising acetylcholine levels in the brain to help manage the cognitive decline seen in Alzheimer's disease and Parkinson's disease dementia.
- Treatment starts at a low dose of 1.5 mg twice daily and is titrated upward in steps of 1.5 mg twice daily at intervals of at least two weeks to minimize gastrointestinal adverse effects; the maximum recommended dose is 6 mg twice daily.
- The most common side effects are nausea, vomiting, diarrhea, dizziness, and decreased appetite. These typically occur during dose escalation and often lessen as the body adjusts to the medication.
- Rivastigmine should not be combined with other cholinesterase inhibitors (donepezil, galantamine) or with metoclopramide. Caution is required with beta-blockers, QT-prolonging drugs, and succinylcholine-type muscle relaxants used during anesthesia.
- If treatment is interrupted for more than three consecutive days, patients must speak with their doctor before resuming. The dose will typically need to be restarted at a lower level to prevent severe gastrointestinal adverse effects.
What Is Rivastigmine and What Is It Used For?
Rivastigmine contains the active substance rivastigmine hydrogen tartrate, a carbamate derivative that belongs to a class of medications known as cholinesterase inhibitors. This class of drugs has served as the cornerstone of symptomatic pharmacotherapy for Alzheimer's disease for more than two decades and is recommended by the World Health Organization (WHO), the European Medicines Agency (EMA), the United States Food and Drug Administration (FDA), and the United Kingdom's National Institute for Health and Care Excellence (NICE). Rivastigmine is considered distinct within this therapeutic class because it inhibits two enzymes involved in acetylcholine breakdown – acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) – whereas most other cholinesterase inhibitors such as donepezil and galantamine primarily target AChE alone.
In patients with dementia caused by Alzheimer's disease or by Parkinson's disease, progressive loss of nerve cells occurs in specific regions of the brain, particularly in areas responsible for memory, learning, attention, and executive function. One of the critical biochemical consequences of this neurodegeneration is a marked reduction in the neurotransmitter acetylcholine, a chemical messenger that enables communication between nerve cells in the central nervous system. Acetylcholine plays an essential role in attention, working memory, learning, and higher cognitive processing. The progressive loss of cholinergic neurons in the basal forebrain and their projections to the cortex and hippocampus correlates strongly with the severity of cognitive decline observed in these diseases.
Rivastigmine works by reversibly inhibiting the enzymes that break down acetylcholine in the brain. By blocking both acetylcholinesterase and butyrylcholinesterase, rivastigmine prevents the degradation of acetylcholine at cholinergic synapses, thereby increasing its concentration and prolonging its action at neuronal receptors. This enhanced cholinergic neurotransmission can help improve or stabilize cognitive function, the ability to perform activities of daily living, and behavioral symptoms in affected patients. It is important to understand, however, that rivastigmine does not cure Alzheimer's disease or Parkinson's disease dementia; the medication addresses the cholinergic deficit but does not halt the underlying neurodegenerative process. Rather, it provides symptomatic relief and may slow the rate of cognitive and functional decline in responsive patients.
Rivastigmine is specifically approved for two indications in adult patients:
- Mild to moderately severe Alzheimer's disease dementia: Alzheimer's disease is the most common cause of dementia worldwide, accounting for approximately 60–70% of all dementia cases according to the World Health Organization. Globally, more than 55 million people live with dementia, and this number is projected to nearly triple by 2050. Alzheimer's disease is a progressive neurodegenerative disorder characterized by gradual decline in memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. The disease typically progresses over several years, moving from mild forgetfulness and subtle changes in daily function to severe impairment in all areas of cognition and self-care. Large randomized controlled trials have shown that rivastigmine improves or stabilizes cognition, daily function, and global clinical impression in patients with mild to moderate Alzheimer's disease.
- Dementia associated with Parkinson's disease: Parkinson's disease is a neurodegenerative disorder best known for its motor features (resting tremor, rigidity, bradykinesia, and postural instability), but cognitive impairment and dementia are frequent complications, especially in the advanced stages of the illness. Parkinson's disease dementia (PDD) affects an estimated 20–40% of patients with Parkinson's disease during the course of their illness and is characterized by prominent deficits in attention, executive function, and visuospatial abilities, as well as memory impairment. Rivastigmine is the only cholinesterase inhibitor specifically approved by the European Medicines Agency for the treatment of PDD, an approval based on evidence from the EXPRESS trial (published in the New England Journal of Medicine, 2004) which demonstrated significant improvements in cognition and activities of daily living.
Unlike other cholinesterase inhibitors such as donepezil, which target only acetylcholinesterase, rivastigmine also inhibits butyrylcholinesterase. Research has shown that butyrylcholinesterase activity actually increases in the brains of patients with Alzheimer's disease as the disease progresses, while acetylcholinesterase activity decreases. This dual inhibition may therefore become increasingly relevant in later stages of disease, potentially offering a more sustained therapeutic benefit over time. Rivastigmine is also described as a "pseudo-irreversible" inhibitor because although it binds and inhibits the enzymes reversibly, the duration of enzyme inhibition in the central nervous system (~10 hours) far exceeds the drug's short plasma half-life (~1–2 hours).
Rivastigmine is manufactured and distributed globally by multiple pharmaceutical companies. Well-known brand names include the originator product Exelon (developed by Novartis) and numerous generic formulations marketed under names such as Rivastigmine 1 A Pharma, Rivastigmine Actavis, Rivastigmine Stada, Rivastigmine Orion, and Rivastigmine Teva. In capsule form, rivastigmine is available in four strengths – 1.5 mg, 3 mg, 4.5 mg, and 6 mg – allowing for careful dose titration. Rivastigmine is also available as a transdermal patch from selected manufacturers; the patch offers a different pharmacokinetic profile with steadier plasma concentrations and is generally associated with fewer gastrointestinal side effects than oral capsules, making it a useful option for patients who have difficulty swallowing or who do not tolerate the capsules.
The decision to initiate rivastigmine therapy is typically made by a physician with expertise in diagnosing and managing dementia, such as a neurologist, geriatrician, or old-age psychiatrist. Treatment initiation generally follows confirmation of the diagnosis of mild to moderately severe dementia using standardized diagnostic criteria and cognitive assessment tools. Baseline cognitive, functional, and behavioral assessments establish a reference point against which future response to therapy can be measured.
What Should You Know Before Taking Rivastigmine?
Contraindications
There are specific situations in which rivastigmine must not be used. Understanding these absolute contraindications is essential before starting treatment and must be reviewed with the prescribing physician.
- Hypersensitivity: Do not take rivastigmine if you are allergic to rivastigmine, to other carbamate derivatives, or to any of the inactive ingredients in the capsules (such as magnesium stearate, colloidal silicon dioxide, hypromellose, microcrystalline cellulose, gelatin, titanium dioxide, or iron oxides). Hypersensitivity reactions may include skin rash, itching, swelling of the face, lips or tongue, and in rare cases anaphylaxis.
- Previous severe skin reaction to rivastigmine patch: If you have previously used a rivastigmine transdermal patch and experienced a skin reaction that spread beyond the patch area, an intense local reaction (such as blistering, increasing skin inflammation, or swelling), or a reaction that did not improve within 48 hours of removing the patch, you should not take rivastigmine capsules. Such reactions may represent allergic contact sensitization and may predispose to a more serious systemic hypersensitivity reaction on oral re-exposure.
Warnings and Precautions
Before and during treatment with rivastigmine, tell your doctor if any of the following conditions apply to you. These circumstances do not necessarily preclude use of the medication, but they require closer monitoring, cautious dose titration, or, in some cases, a different therapeutic approach.
- Heart conditions: If you have or have ever had an irregular or slow heartbeat, sick sinus syndrome, cardiac conduction abnormalities, QTc interval prolongation on ECG, a family history of QTc prolongation or torsades de pointes, or low blood levels of potassium or magnesium. Cholinesterase inhibitors can cause bradycardia (slow heart rate) through their vagotonic (parasympathomimetic) effects, and rivastigmine may exacerbate pre-existing cardiac conduction abnormalities. Fainting (syncope) has been reported in patients with cardiac risk factors.
- Active peptic ulcer or history of gastrointestinal bleeding: Cholinesterase inhibitors increase gastric acid secretion as a direct consequence of their pharmacological action. If you have or have ever had a stomach or duodenal ulcer, or a history of gastrointestinal bleeding, you may be at increased risk of ulceration and bleeding during treatment. Your doctor will monitor you carefully and may co-prescribe a proton pump inhibitor for gastroprotection, particularly if you also take NSAIDs or anticoagulants.
- Urinary difficulties: If you have or have ever had problems with urination or any form of urinary obstruction, rivastigmine may worsen these symptoms because of its cholinergic effects on bladder smooth muscle. Urinary retention has been reported in rare cases during treatment.
- Seizures: Cholinergic drugs have the potential to trigger generalized seizures in susceptible individuals. While seizures may also be a manifestation of Alzheimer's disease itself, this potential risk should be considered when prescribing rivastigmine to patients with a history of seizure disorders or risk factors for seizures.
- Asthma or respiratory disease: If you have asthma, chronic obstructive pulmonary disease (COPD), or other serious respiratory conditions, rivastigmine may increase bronchoconstriction and bronchial secretions due to its cholinergic activity, potentially worsening respiratory function. Use should be cautious, with monitoring for any worsening of respiratory symptoms.
- Kidney or liver impairment: Although rivastigmine is primarily metabolized by cholinesterase-mediated hydrolysis rather than by hepatic cytochrome P450 enzymes, patients with significant renal or hepatic disease may experience altered drug exposure. Your doctor may elect to use slower dose titration and more frequent monitoring in such cases.
- Low body weight: Patients weighing less than 50 kg (approximately 110 lb) may be more susceptible to adverse effects, particularly gastrointestinal symptoms and weight loss. Regular weight monitoring is recommended throughout treatment, and dose adjustments may be needed to balance efficacy with tolerability.
- Tremor and extrapyramidal symptoms: Rivastigmine may worsen or precipitate extrapyramidal symptoms, including tremor. This is particularly relevant for patients with Parkinson's disease dementia, in whom rivastigmine may transiently aggravate motor symptoms despite its cognitive benefits. Close clinical monitoring is advisable, and consultation with the patient's movement disorders specialist may be helpful.
If you have not taken rivastigmine for more than three consecutive days, do not take the next dose until you have spoken with your doctor. Restarting at the previous dose after an interruption of more than three days can cause severe gastrointestinal symptoms, including intense nausea and vomiting, and, in rare cases, esophageal rupture due to forceful vomiting. Your doctor will usually restart treatment at the lowest dose (1.5 mg twice daily) and re-titrate gradually to the previous maintenance dose.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, seek advice from your doctor or pharmacist before taking this medicine. Given the typical age of onset of Alzheimer's disease and Parkinson's disease dementia, pregnancy is uncommon among patients taking rivastigmine, but it remains important to understand the potential risks if the medication is prescribed for rarer indications in younger patients or when off-label use is considered.
Use in pregnancy should be avoided unless clearly necessary. There are limited data on the use of rivastigmine in pregnant women. Animal reproductive studies have not demonstrated direct harmful effects on pregnancy or fetal development at therapeutic doses, but the absence of adequate human data means that any use during pregnancy should follow careful benefit-risk assessment by a specialist physician.
You should not breastfeed while taking rivastigmine. In animal studies, rivastigmine was found to be excreted in breast milk, and a risk to the nursing infant cannot be excluded. If treatment with rivastigmine is essential, breastfeeding should be discontinued or an alternative medication should be considered.
Driving and Operating Machinery
Your doctor will advise you whether your underlying condition allows you to safely drive or operate machinery. Rivastigmine itself may cause dizziness, drowsiness, syncope, and, in some cases, delirium, particularly at the start of treatment or when the dose is increased. If you feel dizzy or drowsy, do not drive, operate machinery, or perform any tasks that require alertness until these effects have resolved. In addition, the underlying dementia itself may impair driving ability regardless of medication, and formal assessment of fitness to drive should be considered for all patients with dementia.
How Does Rivastigmine Interact with Other Drugs?
Tell your doctor or pharmacist about all medications you are currently taking, have recently taken, or might take – including prescription medicines, over-the-counter drugs, herbal supplements, and vitamins. Although rivastigmine is primarily metabolized by cholinesterase-mediated hydrolysis and has minimal interaction with the hepatic cytochrome P450 enzyme system, several clinically important drug interactions do exist. These interactions arise mainly from rivastigmine's cholinergic pharmacological activity and its effects on heart rate, gastric acid secretion, and neuromuscular function. Recognizing these interactions is essential for safe and effective use of the medication, particularly in elderly patients who frequently take multiple concurrent medications.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Other cholinesterase inhibitors (donepezil, galantamine) | Additive cholinergic effects; markedly increased risk of severe adverse reactions including cholinergic crisis | Do not combine – only one cholinesterase inhibitor should be prescribed at a time |
| Metoclopramide (used for nausea and gastroparesis) | Risk of extrapyramidal symptoms including joint stiffness, hand tremors, and involuntary movements | Avoid combination; alternative antiemetics such as ondansetron are preferred |
| Beta-blockers (atenolol, metoprolol, bisoprolol, propranolol) | Additive bradycardia (slow heart rate) which may lead to syncope (fainting) or, rarely, complete heart block | Use with caution; monitor heart rate regularly; cardiology consultation may be warranted |
| QT-prolonging drugs (certain antiarrhythmics, antipsychotics, macrolide antibiotics, fluoroquinolones) | Potential additive effect on cardiac QT interval prolongation with risk of torsades de pointes and other serious arrhythmias | Use with caution; ECG monitoring may be warranted, particularly in patients with other cardiac risk factors |
| Beta-agonist bronchodilators (salbutamol/albuterol, salmeterol) | Theoretical pharmacological antagonism; rivastigmine may counteract the bronchodilating effect | Monitor respiratory symptoms in patients with asthma or COPD; dose adjustment rarely required |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Anticholinergic agents (oxybutynin, tolterodine, benztropine, some antihistamines) | May counteract the cholinergic effects of rivastigmine, reducing its therapeutic benefit on cognition | Avoid where possible; review ongoing need for anticholinergic therapy; consider alternatives |
| Succinylcholine-type muscle relaxants | Rivastigmine may prolong the neuromuscular blocking effect of depolarizing muscle relaxants administered during general anesthesia | Inform the anesthesiologist before any surgery; dose adjustments of relaxant or choice of a non-depolarizing agent may be needed |
| NSAIDs (ibuprofen, naproxen, diclofenac, aspirin) | Both rivastigmine (increased gastric acid) and NSAIDs increase the risk of gastrointestinal ulceration and bleeding | Use with caution; consider gastroprotection with a proton pump inhibitor where long-term NSAID use is required |
| Cholinergic agonists (bethanechol, pilocarpine) | Additive cholinergic stimulation; increased risk of cholinergic adverse effects such as sweating, salivation, bradycardia, and bronchospasm | Use with caution; monitor for excessive cholinergic stimulation |
| Tobacco (nicotine) | Chronic nicotine use may increase rivastigmine clearance by approximately 23% | Generally not clinically significant; dose adjustments rarely required |
Before any surgical procedure or dental work under general anesthesia, it is essential to tell your surgeon and anesthesiologist that you are taking rivastigmine. The medication may exaggerate the effects of succinylcholine-type (depolarizing) muscle relaxants used during general anesthesia, potentially leading to prolonged neuromuscular blockade and respiratory complications. With adequate planning, dose adjustment of the muscle relaxant or selection of a non-depolarizing neuromuscular blocking agent can mitigate this risk. The rivastigmine itself is usually continued perioperatively unless there is a specific reason to withhold it, but this decision should be made in consultation with the prescribing physician.
It is worth noting that rivastigmine has a low potential for pharmacokinetic drug interactions mediated through the cytochrome P450 enzyme system, because it is metabolized primarily by cholinesterase-mediated hydrolysis at the site of enzyme inhibition. This means that, unlike many other centrally acting medications, rivastigmine is unlikely to significantly alter the blood levels of drugs metabolized by enzymes such as CYP2D6, CYP3A4, or CYP1A2, and is itself not substantially affected by inhibitors or inducers of these enzymes.
What Is the Correct Dosage of Rivastigmine?
Always take rivastigmine exactly as your doctor has instructed. If you are unsure about any aspect of the dosing, consult your doctor, pharmacist, or nurse. The dose of rivastigmine is always individualized based on each patient's response and tolerance to the medication, and slow, gradual dose titration is essential to minimize gastrointestinal side effects, which are the most common reason for treatment discontinuation.
| Patient Group | Starting Dose | Titration | Maximum Dose |
|---|---|---|---|
| Adults (Alzheimer's disease dementia) | 1.5 mg twice daily | Increase by 1.5 mg twice daily every 2 weeks | 6 mg twice daily (12 mg/day) |
| Adults (Parkinson's disease dementia) | 1.5 mg twice daily | Increase by 1.5 mg twice daily every 4 weeks | 6 mg twice daily (12 mg/day) |
| Elderly (≥65 years) | 1.5 mg twice daily (no specific adjustment) | Same as adults, with careful monitoring | 6 mg twice daily |
| Low body weight (<50 kg) | 1.5 mg twice daily | May require slower titration | May tolerate only lower maintenance doses |
| Renal or hepatic impairment | 1.5 mg twice daily | Titrate according to individual tolerance | Individualized based on response |
| Children and adolescents | Not indicated | Not applicable | Not applicable |
Adults
Starting Dose
Dose: 1.5 mg twice daily (total 3 mg per day)
Duration: At least 2 weeks at this dose (4 weeks in Parkinson's disease dementia) before any dose increase
Treatment is always initiated at the lowest available strength to allow the body to adjust to the cholinergic effects of the medication. The capsules should be taken with food – once in the morning and once in the evening.
Dose Titration
Increments: Increase by 1.5 mg twice daily at intervals of at least 2 weeks (Alzheimer's disease) or 4 weeks (Parkinson's disease dementia)
Titration schedule: 1.5 mg → 3 mg → 4.5 mg → 6 mg twice daily
Before each dose increase, your doctor will assess your tolerance and response. If side effects such as nausea, vomiting, or diarrhea are troublesome, the dose increase may be delayed, or the dose may be temporarily reduced to the previous well-tolerated level before attempting the next increment again.
Maintenance Dose
Effective therapeutic dose: 3 mg to 6 mg twice daily
Maximum dose: 6 mg twice daily (total 12 mg per day)
Your doctor will regularly evaluate whether the treatment is achieving its intended effects on cognitive function and activities of daily living. If clinical benefit is no longer evident, or if adverse effects outweigh the benefits, continuing therapy may need to be reconsidered. Regular weight monitoring is also recommended during long-term treatment.
Children
Rivastigmine is not indicated for use in children or adolescents. There is no relevant clinical use of rivastigmine in the pediatric population for the treatment of Alzheimer's disease or Parkinson's disease dementia, as these are age-related neurodegenerative conditions that primarily affect older adults. Rivastigmine should therefore not be prescribed to patients under 18 years of age outside of carefully controlled research settings.
Elderly Patients
The vast majority of patients taking rivastigmine are elderly. No specific dose adjustment is required based on age alone, and the same titration schedule as for younger adults applies. However, elderly patients may be more susceptible to adverse effects, particularly gastrointestinal symptoms, weight loss, dizziness, syncope, and falls. Careful dose titration with close monitoring at each step is essential. Patients with low body weight (under 50 kg), which is more common in the very elderly, may experience adverse effects more frequently and may need slower titration or lower maintenance doses.
How to Take Rivastigmine
- Take the capsules twice daily: once in the morning and once in the evening, aiming for approximately 12-hour intervals between doses.
- Always take the capsules with food. Taking the capsules with a meal slows absorption, reduces peak plasma concentration, and significantly improves gastrointestinal tolerability.
- Swallow the capsules whole with a glass of water or another non-alcoholic drink. Do not open, crush, chew, or split the capsules, as this can affect how the drug is absorbed and may increase side effects.
- Tell your caregiver that you are taking rivastigmine, as they may need to help remind you to take your doses on schedule. Using a pill organizer or a smartphone reminder is often helpful for patients with memory impairment.
- Take the medication every day for it to be effective. Do not skip doses and do not stop treatment abruptly without consulting your doctor.
Missed Dose
If you forget to take a dose, simply wait until your next scheduled dose and take it at the usual time. Do not take a double dose to compensate for a forgotten dose, as this increases the risk of cholinergic side effects without providing any additional therapeutic benefit. If you have not taken rivastigmine for more than three consecutive days, you must contact your doctor before taking the next dose. Restarting at the previous dose after such an interruption can cause severe gastrointestinal symptoms. Your doctor will typically restart treatment from the lowest dose (1.5 mg twice daily) and gradually re-titrate upward over several weeks.
Overdose
If you or someone in your care accidentally takes more rivastigmine than prescribed, contact your doctor or poison control center immediately. Urgent medical attention may be required. Symptoms of overdose typically reflect exaggerated cholinergic activity and may include severe nausea, vomiting, diarrhea, abdominal cramps, sweating, salivation, urinary incontinence, hypertension, muscle weakness, bradycardia, hypotension, respiratory depression, hallucinations, convulsions, and, in severe cases, collapse and loss of consciousness (cholinergic crisis).
There is no specific antidote for rivastigmine overdose; treatment is supportive and symptomatic. Because rivastigmine has a short plasma half-life (~1–2 hours), most patients will recover with observation and supportive care. Atropine sulfate may be used intravenously as an initial pharmacological antidote in cases of severe cholinergic toxicity, with doses titrated to clinical response. Cases of intentional overdose or ingestion by children require emergency evaluation in a hospital setting.
What Are the Side Effects of Rivastigmine?
Like all medicines, rivastigmine can cause side effects, although not everyone who takes it will experience them. Side effects are most likely to occur during the first few weeks of treatment or when the dose is increased during titration. In most cases, side effects gradually diminish as the body adjusts to the medication, and patients who tolerate the titration phase often remain on maintenance therapy with minimal ongoing adverse effects. Your doctor should monitor you regularly throughout treatment and adjust the dose if side effects become troublesome.
Very Common
- Dizziness
- Decreased appetite
- Nausea
- Vomiting
- Diarrhea
Common
- Anxiety and agitation
- Excessive sweating
- Headache
- Heartburn (dyspepsia)
- Weight loss
- Abdominal pain
- Feeling of restlessness or confusion
- Fatigue or weakness (asthenia)
- General feeling of being unwell (malaise)
- Trembling (tremor)
- Drowsiness (somnolence)
- Nightmares and unusual dreams
Uncommon
- Depression
- Difficulty sleeping (insomnia)
- Fainting (syncope) and accidental falls
- Elevated liver function tests (transaminases)
Rare and Very Rare
- Chest pain (angina pectoris)
- Skin rash and itching (pruritus)
- Seizures (convulsions)
- Gastric and duodenal ulcers
- High blood pressure (hypertension)
- Urinary tract infection
- Hallucinations (seeing things that are not real)
- Cardiac rhythm disturbances (both fast and slow heart rate)
- Gastrointestinal bleeding (blood in stool or vomit)
- Pancreatitis (severe upper abdominal pain with nausea and vomiting)
- Worsening of Parkinson's disease symptoms (muscle rigidity, difficulty moving)
- Severe vomiting potentially causing esophageal rupture
- Dehydration (from excessive fluid loss)
- Liver disorders (jaundice, dark urine, unexplained fatigue and loss of appetite)
- Aggression and restlessness
- Pisa syndrome (involuntary lateral bending of the trunk and head)
- Severe skin reactions (Stevens-Johnson syndrome – very rare)
Additional Side Effects in Patients with Parkinson's Disease Dementia
Patients with dementia associated with Parkinson's disease may experience certain side effects more frequently than patients treated for Alzheimer's disease dementia, or may develop additional adverse effects that are less commonly seen in Alzheimer's disease. This is partly due to interactions between rivastigmine and the underlying Parkinsonian pathology and partly due to concurrent dopaminergic therapy. Reported additional effects include:
- Very common: Tremor (worsening of existing tremor), accidental falls.
- Common: Anxiety, restlessness, slow and fast heart rate, sleep disturbances, excessive salivation, dehydration, abnormally slow or uncontrolled movements (dyskinesia), worsening of Parkinsonian symptoms (rigidity, difficulty initiating movement, muscle weakness), visual hallucinations, depression, high blood pressure.
- Uncommon: Irregular heart rhythm, poor movement control, orthostatic hypotension (low blood pressure on standing).
Many of the gastrointestinal side effects (nausea, vomiting, diarrhea, decreased appetite) are dose-related and most prominent during dose escalation. They typically improve over days to weeks as the body adjusts to each new dose. Strategies to reduce these effects include always taking the capsules with food, ensuring adequate hydration, avoiding large or greasy meals around the time of dosing, and, if necessary, slowing the titration schedule under medical supervision. Switching to the transdermal patch formulation (where available) may substantially reduce gastrointestinal intolerance in patients who cannot tolerate the capsules.
Contact your doctor immediately, or seek emergency medical care, if you experience severe or persistent vomiting, signs of dehydration (dry mouth, decreased urination, dark urine), chest pain, fainting, seizures, signs of liver problems (yellowing of the skin or eyes, very dark urine, unexplained fatigue), severe abdominal pain radiating to the back (possible pancreatitis), signs of gastrointestinal bleeding (black tarry stools, blood in vomit), or new severe skin reactions with blistering or peeling. These may indicate serious complications that require prompt medical attention and possibly discontinuation of the medication.
Any suspected adverse drug reaction should be reported to the prescribing physician, who may also submit a report to the national pharmacovigilance authority (such as the FDA MedWatch program in the United States, the EMA EudraVigilance system in Europe, or the MHRA Yellow Card Scheme in the United Kingdom). Patient reporting of adverse drug reactions contributes to ongoing post-marketing safety surveillance.
How Should You Store Rivastigmine?
Proper storage of any medication is essential to maintain its chemical stability, effectiveness, and safety. Rivastigmine capsules should be stored in a cool, dry place at a temperature not exceeding 25°C (77°F). Do not store the capsules in the bathroom, near a kitchen sink, or on a windowsill, because humidity, direct sunlight, and fluctuating temperatures can damage the medication over time. Keep the capsules in their original blister packaging until you are ready to take them. The blister pack is designed to protect the product from moisture, light, and oxygen.
Keep rivastigmine out of the sight and reach of children. Accidental ingestion of rivastigmine by a child can cause serious adverse effects, including severe gastrointestinal symptoms and, in large ingestions, cholinergic crisis that can be life-threatening. Because the 1.5 mg, 3 mg, 4.5 mg, and 6 mg capsules have attractive, brightly colored shells, they may be mistaken for sweets by children. Store the medication in a locked cabinet or on a high shelf inaccessible to children. If a child accidentally swallows rivastigmine capsules, call your local poison control center or seek emergency medical attention immediately.
Do not use rivastigmine after the expiry date stated on the carton and blister pack. The expiry date refers to the last day of the stated month. Using expired medication may result in reduced effectiveness or, in rare cases, produce degradation products that could be harmful. Check the expiry date each time you refill your prescription, and inform your pharmacist if you notice any discoloration, unusual odor, or physical changes in the capsules before taking them.
Do not dispose of medications in household waste, and do not pour them into sinks, toilets, or other wastewater. Return any unused or expired capsules to your pharmacist for proper disposal. Many pharmacies operate formal take-back programs for unused medications, and local health authorities often organize periodic collection events. These measures help protect the environment from pharmaceutical contamination of water supplies and prevent accidental ingestion by children or pets who might otherwise come into contact with discarded medication.
What Does Rivastigmine Contain?
Each rivastigmine capsule contains rivastigmine in the form of rivastigmine hydrogen tartrate as the active substance. The capsules are available in four standardized strengths, each containing a different amount of rivastigmine base equivalent:
| Strength | Capsule Color (Typical) | Contents |
|---|---|---|
| 1.5 mg | Yellow cap and yellow body | Off-white to slightly yellowish powder |
| 3 mg | Orange cap and orange body | Off-white to slightly yellowish powder |
| 4.5 mg | Red cap and red body | Off-white to slightly yellowish powder |
| 6 mg | Red cap and orange body | Off-white to slightly yellowish powder |
The other (inactive) ingredients in rivastigmine capsules vary slightly between manufacturers but typically include the following:
- Capsule contents: Magnesium stearate (lubricant), colloidal silicon dioxide (flow agent, also called colloidal anhydrous silica), hypromellose (binder), and microcrystalline cellulose (filler). These excipients ensure uniform capsule content, consistent drug release, and satisfactory stability of the formulation over its shelf life.
- Capsule shell: Gelatin (the main structural component of the shell), titanium dioxide (E171, white colorant and opacifier), and iron oxides (E172, yellow and/or red colorants depending on the strength). The different color combinations help both patients and caregivers distinguish between the four available strengths, which is particularly important during dose titration and reduces the risk of dosing errors.
Rivastigmine capsules are typically available in blister packs of 28, 56, or 112 capsules, as well as in bottles containing 250 capsules. Not all pack sizes may be available in every country, and exact inactive ingredient lists may vary between brands and between national formulations. Refer to the patient information leaflet supplied with your specific pack for definitive composition information, and discuss any known excipient allergies (for example to iron oxides or gelatin) with your pharmacist before starting treatment.
Alongside oral capsules, rivastigmine is also available in some countries as a transdermal patch (for example at 4.6 mg/24 h, 9.5 mg/24 h, and 13.3 mg/24 h delivery rates). Patches offer an alternative route of administration that may be preferred for patients who cannot swallow capsules or who experience significant gastrointestinal side effects with oral therapy. The transdermal formulation is beyond the scope of this article but is discussed with prescribers when capsule therapy is not well tolerated.
Frequently Asked Questions
Rivastigmine is a dual cholinesterase inhibitor, meaning it blocks both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). This distinguishes it from donepezil (Aricept) and galantamine (Reminyl), which primarily inhibit AChE alone. The clinical significance of this dual inhibition is that butyrylcholinesterase becomes increasingly important in the brain as Alzheimer's disease progresses. Memantine, another Alzheimer's medication, works through a completely different mechanism (NMDA receptor antagonism) and is typically used in moderate to severe disease, sometimes in combination with a cholinesterase inhibitor. Rivastigmine is also the only cholinesterase inhibitor specifically approved for Parkinson's disease dementia. Your doctor will recommend the most appropriate medication based on your specific situation, other conditions, and tolerance profile.
Yes, rivastigmine can be safely used in combination with memantine. These two medications work through complementary mechanisms – rivastigmine increases acetylcholine levels while memantine modulates excessive glutamate activity at NMDA receptors. Combination therapy is commonly used in clinical practice for patients with moderate to severe Alzheimer's disease. Several clinical studies and meta-analyses have suggested that combination therapy may provide modest additional benefits in terms of cognition, function, and behavior compared with either drug alone, although the magnitude of benefit is typically small. Your doctor will determine whether combination therapy is appropriate for your specific case, usually by adding memantine to an established rivastigmine regimen as the disease progresses.
The effects of rivastigmine develop gradually over several weeks to months. Because treatment starts at a low dose and is slowly increased, it typically takes 12 to 26 weeks (3 to 6 months) to reach the optimal maintenance dose and to assess the full therapeutic effect. Some patients or their caregivers may notice subtle improvements in attention, alertness, or daily functioning within the first few weeks, but meaningful clinical benefit usually becomes apparent only after reaching and maintaining the optimal dose for several weeks. Your doctor will regularly evaluate whether the medication is having its intended effect using cognitive tests (such as the Mini-Mental State Examination), functional assessments, and caregiver interviews. A trial of 3–6 months is usually required before concluding that treatment is or is not effective.
Caregivers play a crucial role in ensuring safe and effective treatment with rivastigmine. Key responsibilities include: ensuring the medication is taken twice daily with food at consistent times; monitoring for side effects such as nausea, vomiting, weight loss, fainting, or excessive drowsiness; keeping an accurate record of any missed doses and contacting the doctor if the patient misses more than three days in a row; observing for changes in behavior, mood, or cognitive function that may indicate benefit or adverse effects; ensuring the patient attends regular follow-up appointments for clinical monitoring; and keeping the medication securely stored away from children. Caregivers should also understand that rivastigmine does not stop the progression of dementia but may help maintain function for longer, and that its effects are best judged over months rather than days.
Both contain the same active ingredient (rivastigmine) and work through the same mechanism, but they are different formulations with distinct pharmacokinetic characteristics. Rivastigmine capsules are oral and taken twice daily, while the rivastigmine patch (transdermal formulation) is applied to the skin once daily. The patch provides more steady drug levels throughout the day and is generally associated with fewer gastrointestinal side effects (less nausea and vomiting) because it avoids the high peak plasma concentrations that can occur after oral dosing. However, the patch can cause skin reactions at the application site, such as redness, itching, and occasionally blistering, and the site must be rotated daily. Your doctor can help you decide which formulation is most appropriate based on your needs, preferences, tolerance, and ability to swallow capsules reliably.
No, rivastigmine is not used to prevent Alzheimer's disease and has not been shown to have preventive effects. It is a symptomatic treatment intended only for patients who have already been diagnosed with mild to moderately severe Alzheimer's disease dementia or Parkinson's disease dementia. Large clinical trials in patients with mild cognitive impairment have not demonstrated that cholinesterase inhibitors prevent or delay progression to dementia. Current research into prevention is focused on other targets, including amyloid-lowering therapies, anti-tau agents, lifestyle interventions, cardiovascular risk management, and hearing health. Cholinesterase inhibitors like rivastigmine remain symptomatic treatments that address the cholinergic deficit once dementia is established, rather than modifying the underlying disease process.
Any decision to discontinue rivastigmine should be made in consultation with your doctor. There are several valid reasons to consider stopping, including intolerable side effects, lack of evident benefit after an adequate trial, advanced progression of the underlying disease, or development of significant medical conditions that change the risk-benefit balance. Stopping rivastigmine does not cause physical dependence or a classical withdrawal syndrome, but some patients may experience a temporary decline in cognition and function when the medication is withdrawn. This reflects loss of the drug's symptomatic effect rather than disease acceleration. If your doctor decides to stop treatment, this is typically done gradually, and the patient is reassessed after several weeks to determine whether restarting is warranted.
References
- European Medicines Agency (EMA). Rivastigmine – Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu
- Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews. 2015;(4):CD001191. doi:10.1002/14651858.CD001191.pub4
- National Institute for Health and Care Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Technology Appraisal Guidance [TA217]. Updated 2023. Available at: www.nice.org.uk/guidance/ta217
- Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine. 2004;351(24):2509-2518. doi:10.1056/NEJMoa041470
- World Health Organization (WHO). Dementia Fact Sheet. 2023. Available at: www.who.int
- American Academy of Neurology (AAN). Practice Parameter: Management of Dementia (an evidence-based review). Updated 2024.
- Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for Alzheimer's disease and Parkinson's disease dementia. Annals of the New York Academy of Sciences. 2010;1199:167-174.
- U.S. Food and Drug Administration (FDA). Exelon (rivastigmine tartrate) – Prescribing Information. Latest revision on file with the FDA.
- Joint Formulary Committee. British National Formulary (BNF). London: BMJ Group and Pharmaceutical Press. Updated 2025. Available at: bnf.nice.org.uk
- Darreh-Shori T, Soininen H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies. Current Alzheimer Research. 2010;7(1):67-73.
Editorial Team
This article has been written and reviewed by medical professionals to ensure clinical accuracy and adherence to current evidence-based guidelines.
Medical Content
iMedic Medical Editorial Team – Specialists in Neurology, Geriatric Medicine, and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following WHO, EMA, FDA, and NICE guidelines
Evidence Standard
Level 1A – Systematic reviews and meta-analyses of randomized controlled trials (GRADE framework)
Last Review
February 4, 2026 – Next scheduled review within 12 months
Conflict of Interest Declaration: The iMedic editorial team has no financial relationships with pharmaceutical companies. All content is independently produced without commercial sponsorship or advertising influence. Our editorial standards are published at iMedic Editorial Standards.